Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | ESRRG | P62508 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30826984 | 0.86 | ESR1 (0.49) | ESR1ESR2DEGS1LMNATYR | |
| SCHEMBL6919625 | 0.80 | CCR1 (0.41) | HSD17B10 | |
| SCHEMBL30189703 | 0.80 | KDM4E (0.38) | HSD17B10 | |
| SCHEMBL19782445 | 0.80 | KDM4E (0.38) | HSD17B10 | |
| SCHEMBL1820902 | 0.78 | GBA1 (0.43) | TSHR | |
| SCHEMBL25150684 | 0.76 | ESR1 (0.40) | ESR1ESR2LMNA | |
| SCHEMBL28769415 | 0.74 | ESR1 (0.46) | ESR1ESR2DEGS1LMNACYP3A4 | |
| SCHEMBL807517 | 0.74 | — | — | |
| SCHEMBL27850881 | 0.73 | ESR1 (0.39) | ESR1ESR2DEGS1LMNACYP3A4 | |
| SCHEMBL3996503 | 0.73 | ESR1 (0.41) | ESR1ESR2DEGS1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906532-B2 | Antiserotonine agents; gastrointestinal disorders; irritable bowel syndrome; central nervous system disorders; Alzheimer's disease; cognition activators; analgesics; cardiovascular disorders; antidiabetic agents; sleep disorders | PFIZER INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1910340-B1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080269211-A1 | Indazole Derivatives | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1910340-A1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | Pfizer, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010390-A1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269211-A1 | Indazole Derivatives | GPR119, HRH4, HTR4 | ESR1 1868/4885ESR2 1944/4885DEGS1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.